Zimbabwe has turned down a substantial American healthcare agreement worth $367m (£272m) over five years because of the United States' insistence on sensitive data.
This move was revealed after a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official representative has since stated that the United States was requesting biological samples for research and commercial purposes while was unwilling to share the resulting advantages from future treatments.
"We must now begin the challenging and unfortunate task of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged continued negotiations to find a agreement acceptable to all parties so the nation's critical HIV programme can be sustained.
Wider Context
Zimbabwe's decision comes after a similar situation in Kenya, where a court halted a similar deal with the US following concerns were filed about the security of citizens' medical information.
After returning to the presidency last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump claimed its spending was "wasteful" and his government was seeking direct bilateral deals to enhance transparency and responsibility.
Based on reports, 16 African countries have so far signed these new health pacts, representing more than $18.3bn in new funding.
Specifics of the Declined Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration could have provided extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy through American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data over an extended period, with no corresponding guarantee of access to any scientific breakthroughs – such as new medicines or tests – that could be developed from that shared data," he stated.
"Put simply, our nation would provide the basic resources for scientific discovery without any assurance that the final treatments would be accessible to our citizens should a new disease outbreak arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its push of bilateral deals were undermining frameworks previously established via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to manage future pandemics.
"This system is designed to ensure that when a country contributes its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
These objections regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage continued dialogue with our American counterparts on how future collaboration could be designed in a way that honours the independence and dignity of each country."
Medical Community Reaction
Medical experts said it understood the official position, but urged that talks should continue given that a large portion of the nation's HIV programmes depended on foreign aid.
"If specific concerns exist, including those involving information security or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," the group said.
The situation emphasises the complex challenges between receiving much-needed international aid and protecting local interests in an ever more interconnected world.